Encouraging Efficacy and Safety Profile from Ongoing Ph 1 Trial for JANX007 in mCRPC Announced December 9, 2025
First-in-Human Data from Ph 1 Trial of GTA182 in MTAP-Deleted Advanced NSCLC presented December 9, 2025
Clinically Meaningful OS Benefit for Gotistobart in Patients with Previously Treated Squamous NSCLC Announced December 9, 2025
Preliminary Ph 2 Data for Silevertinib in 1L NSCLC and Plans for Ph 2 Trial of Silevertinib in GBM Announced December 9, 2025
Updated Interim Data from Ph 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients Announced December 9, 2025
MVR-T3011 Latest Clinical Results in BCG-Unresponsive NMIBC Patients Demonstrate High Response December 9, 2025
Updated Efficacy Data from Ph 1/2 Transtar102 Trial of Osemitamab + Nivolumab and CAPOX in 1L G/GEJ Cancer Presented December 9, 2025
No median OS difference observed in TNBC patients treated with nadunolimab + gemcitabine/carboplatin (GC) vs GC in Ph 1b/2 TRIFOUR study December 9, 2025
INLEXZO™ (gemcitabine intravesical system) delivers 74% DFS at one year in BCG-unresponsive, high-risk, papillary-only NMIBC December 9, 2025
New Data Announced from Ph 1b/2 EPCORE® CLL-1 Trial of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) December 9, 2025
ORR increases to 82% with additional Partial Response in azer-cel CAR T Relapsed Ph 1b trial December 2, 2025
Ph 3 Trial of Sac-TMT in Combination with KEYTRUDA as 1L Treatment for PD-L1-Positive NSCLC Met Primary Endpoint December 2, 2025
Clinical results of glecirasib in combination with JAB-3312 (sitneprotafib) in KRAS G12C–mutated NSCLC published in The Lancet Respiratory Medicine December 2, 2025
The Annals of Oncology Publishes Results of Ph 2 Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma December 2, 2025
Data from Acclaim-1 Ph 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer December 2, 2025
Update from ongoing TEM-GBM study in newly diagnosed GBM patients with an unmethylated gene promoter announced December 2, 2025
Positive HERIZON-GEA-01 Ph 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted New SOC in 1L HER2+ve LA/M Gastroesophageal Adenocarcinoma November 24, 2025
Statistical analysis of primary efficacy endpoints in Ph 2 trial conducted of MCS-8 (PCP) in prostate cancer completed November 24, 2025
Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML published in the Journal of Hematology & Oncology November 24, 2025
